Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Ascending) Status
70771-1152-00 70771-1152 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec. 5, 2017 In Use
70771-1152-04 70771-1152 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec. 5, 2017 In Use
70771-1152-03 70771-1152 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec. 5, 2017 In Use
68382-0074-01 68382-0074 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec. 5, 2017 In Use
68382-0074-06 68382-0074 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec. 5, 2017 In Use
68382-0074-10 68382-0074 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec. 5, 2017 In Use
68382-0074-77 68382-0074 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec. 5, 2017 In Use
67457-0863-01 67457-0863 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous March 21, 2018 In Use
68083-0161-10 68083-0161 Mesna Injection Mesna 100.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Dec. 20, 2017 In Use
68083-0161-01 68083-0161 Mesna Injection Mesna 100.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Dec. 20, 2017 In Use
55700-0627-10 55700-0627 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 18, 2018 In Use
55700-0627-12 55700-0627 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 18, 2018 In Use
55700-0627-20 55700-0627 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 18, 2018 In Use
55700-0627-30 55700-0627 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 18, 2018 In Use
55700-0631-06 55700-0631 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 25, 2018 In Use
55700-0631-10 55700-0631 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 25, 2018 In Use
55700-0631-20 55700-0631 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 25, 2018 In Use
55700-0631-30 55700-0631 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 25, 2018 In Use
67296-1562-03 67296-1562 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 1, 2018 In Use
25021-0828-50 25021-0828 Leucovorin calcium Leucovorin Calcium 500.0 mg/50mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous April 15, 2018 In Use
54288-0100-01 54288-0100 ZOLEDRONIC ACID ZOLEDRONIC ACID 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous April 2, 2018 In Use
70860-0209-10 70860-0209 Mesna Mesna 100.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Feb. 28, 2018 In Use
70860-0209-11 70860-0209 Mesna Mesna 100.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Feb. 28, 2018 In Use
16714-0815-01 16714-0815 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous May 30, 2018 In Use
68083-0142-01 68083-0142 Zoledronic Acid Zoledronic Acid 4.0 mg/100mL Ancillary Therapy Bisphosphonate Intravenous July 5, 2018 In Use
71332-0005-01 71332-0005 Olutasidenib REZLIDHIA 150.0 mg/1 Chemotherapy Enzyme Inhibitor IDH1 Oral Dec. 1, 2022 In Use
72903-0853-01 72903-0853 Mirvetuximab soravtansine ELAHERE 100.0 mg/20mL Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 Intravenous Nov. 14, 2022 In Use
57894-0449-01 57894-0449 Teclistamab TECVAYLI 10.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct. 25, 2022 In Use
57894-0450-01 57894-0450 Teclistamab TECVAYLI 90.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct. 25, 2022 In Use
00409-5255-25 00409-5255 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Nov. 14, 2022 In Use
00615-8438-39 00615-8438 PREDNISONE Prednisone 1.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov. 1, 2022 In Use
00615-8439-05 00615-8439 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct. 6, 2022 In Use
00615-8439-39 00615-8439 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct. 6, 2022 In Use
00615-8440-05 00615-8440 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct. 27, 2022 In Use
00615-8440-39 00615-8440 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct. 27, 2022 In Use
16571-0817-02 16571-0817 Temozolomide TEMOZOLOMIDE 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0817-51 16571-0817 Temozolomide TEMOZOLOMIDE 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0817-41 16571-0817 Temozolomide TEMOZOLOMIDE 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0818-02 16571-0818 Temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0818-51 16571-0818 Temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0818-41 16571-0818 Temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0819-02 16571-0819 Temozolomide TEMOZOLOMIDE 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0819-51 16571-0819 Temozolomide TEMOZOLOMIDE 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0819-41 16571-0819 Temozolomide TEMOZOLOMIDE 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0820-02 16571-0820 Temozolomide TEMOZOLOMIDE 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0820-51 16571-0820 Temozolomide TEMOZOLOMIDE 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0820-41 16571-0820 Temozolomide TEMOZOLOMIDE 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0821-02 16571-0821 Temozolomide TEMOZOLOMIDE 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0821-51 16571-0821 Temozolomide TEMOZOLOMIDE 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0821-41 16571-0821 Temozolomide TEMOZOLOMIDE 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use

Found 10,000 results in 9 milliseconds — Export these results